Allogene Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Allogene Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 61% to $95,000. The net income raised on -$327,265,000 and profit margin reached -344489%. Total operating expenses were $327,832,000.
Profit Margin
| 2017 | 0 | -2K | |
|---|---|---|---|
| 2018 | 0 | -211.50M | |
| 2019 | 0 | -184.59M | |
| 2020 | 0 | -233.47M | |
| 2021 | 38.48M | -244.83M | -636.12% |
| 2022 | 243K | -329.81M | -135726.34% |
| 2023 | 95K | -327.26M | -344489.47% |
ALLO Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 95K | 243K | 38.48M | 0 | 0 | 0 | 0 |
Cost of revenue | 242.91M | 16.72M | 13.06M | 11.54M | 5.02M | 0 | 0 |
Gross profit | -242.81M | -16.48M | 25.42M | -11.54M | -5.02M | 0 | 0 |
Operating exp. | |||||||
Research and development | 242.91M | 256.38M | 220.17M | 192.98M | 144.53M | 151.86M | 0 |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | -22K |
Total operating expenses | 327.83M | 335.69M | 294.28M | 258.24M | 202.00M | 192.84M | 2K |
Operating income | -327.73M | -335.44M | -255.79M | -258.24M | -202.00M | -192.84M | -2K |
Other income (expenses), net | 472K | 2.81M | -1.21M | 8.02M | 17.08M | -21.21M | -22K |
Income before tax | -327.26M | -332.63M | -257.00M | -250.22M | -184.92M | -211.62M | -2K |
Income tax expense | 0 | -2.81M | -12.16M | -16.75M | -331K | -117K | -24K |
Net income | -327.26M | -329.81M | -244.83M | -233.47M | -184.59M | -211.50M | -2K |
Earnings per share | |||||||
Basic EPS | -2.09 | -2.3 | -1.8 | -1.94 | -1.83 | -7.31 | 0 |
Diluted EPS | -2.09 | -2.3 | -1.8 | -1.94 | -1.83 | -7.31 | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source |